DAVIS, Calif., June 3, 2019 /PRNewswire/ -- Intrexon
Corporation (NASDAQ: XON), a leader in the engineering and
industrialization of biology to improve the quality of life and
health of the planet, today announced it is advancing
GreenVenus™ Romaine lettuce to commercial trials.
Initial data under commercial indoor production conditions indicate
that GreenVenus™ has improved shelf-life up to 2
weeks and a potential for higher marketable yield with no tip
burn. In addition, GreenVenus™ non-browning
lettuce has been assessed by the United States Department of
Agriculture (USDA) and determined not to be subject to regulation
under 7CFR Part 340 for plants altered or produced through genetic
engineering.
![Intrexon GreenVenus Lettuce Intrexon GreenVenus Lettuce](https://mma.prnewswire.com/media/896294/Intrexon_GreenVenus_Lettuce.jpg)
"We are focused on developing new approaches in precision
genetics to enable more sustainable food production as well as
reduce food loss and waste," said Sekhar
Boddupalli, PhD, President of Intrexon's Ag Biotech
Division. "We are pleased to rapidly advance our
GreenVenus™ lettuce with improved marketable yield and
shelf-life from concept to commercial trials within 2 years. The
USDA's transparent, risk-based decision helps clarify the path to
market for our GreenVenus™ (non-transgenic) lettuce and
greatly facilitates our efforts to expand our precision genetics
platform to other vegetables."
"We look forward to continuing our work with our collaborators
and value chain partners as we advance this exciting product toward
commercialization," added Thomas P.
Bostick, PhD, PE, NAE, Chief Operating Officer and
President, Intrexon Bioengineering.
The retail value of leafy greens is estimated at $10B annually in the US. Further, it is
estimated that ~$3.3B worth of
lettuce is lost due to waste each year, half of which is the Romaine type. Non-browning lettuce
can allow for more flexibility in production, processing, shipping
and storage to help reduce the waste of healthy, nutritious food.
As the Company looks to advance this product in development toward
commercialization, standard food and environmental safety
considerations still will
apply to this product prior to introduction.
About Intrexon Corporation
Intrexon Corporation
(NASDAQ: XON) is Powering the Bioindustrial Revolution with Better
DNA™ to create biologically-based products that improve
the quality of life and the health of the planet through two
operating units – Intrexon Health and Intrexon
Bioengineering. Intrexon Health is focused on addressing
unmet medical needs through a diverse spectrum of therapeutic
modalities, including gene and cell therapies, microbial
bioproduction, and regenerative medicine. Intrexon
Bioengineering seeks to address global challenges across food,
agriculture, environmental, and industrial fields by advancing
biologically engineered solutions to improve sustainability and
efficiency. Our integrated technology suite provides
industrial-scale design and development of complex biological
systems delivering unprecedented control, quality, function, and
performance of living cells. We call our synthetic biology approach
Better DNA®, and we invite you to discover more at
www.dna.com or follow us on Twitter at @Intrexon, on Facebook,
and LinkedIn.
Trademarks
Intrexon, GreenVenus, Powering the
Bioindustrial Revolution with Better DNA, and Better DNA are
trademarks of Intrexon and/or its affiliates. Other names may be
trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in
this press release are forward-looking statements. These
forward-looking statements are based upon our current expectations
and projections about future events and generally relate to our
plans, objectives and expectations for the development of our
business. Although management believes that the plans and
objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release.
For more information about Intrexon Corporation,
contact:
Investor
Contact:
Steven
Harasym
Vice President,
Investor Relations
Tel: +1 (301)
556-9850
investors@dna.com
|
Corporate
Contact:
Marie Rossi,
PhD
Vice President,
Communications
Tel: +1 (301)
556-9850
publicrelations@dna.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/intrexon-announces-advances-in-non-browning-greenvenus-romaine-lettuce-300860380.html
SOURCE Intrexon Corporation